|
Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
Bank Loan Ratings | 72.00 | ACUITE B | Downgraded | Issuer not co-operating* | - |
Bank Loan Ratings | 8.00 | - | ACUITE A4 | Reaffirmed | Issuer not co-operating* |
Total Outstanding | 80.00 | - | - |
Rating Rationale |
Acuite has downgraded its long-term rating to ‘ACUITE B’ (read as ACUITE B) from ‘ACUITE B+’ (read as ACUITE B plus) and reaffirmed its short-term rating of ACUITE A4 (read as ACUITE A four) on Rs.80.00 Crore bank facilities of Amogen Pharma Private limited (APPL). The rating is now flagged as “Issuer Not-Cooperating” on account of information risk and is based on the best available information. The rating has been downgraded on account of non-submission of No Default Statement by the company for last 3 consecutive months. |
About the Company |
Amogen Pharma Private Limited, incorporated in 2020. The main objective of the Company is to undertake the business of Bio Pharma Active Pharmaceutical Ingredients manufacturing. At Present, APPL is constructing the factory as per its proposed 1200 KPA (Kgs per annum) Active Pharmaceutical Ingredients (API) manufacturing plant at Karkapatla village, Siddipet district, Telangana. Company has received all the necessary approvals for construction of the plant. The Directors of the company are Mr. Poosapati Venkata Surya Narasimha Raju, Ms. Thakasi Devi Kalyan Kumar and Mr. Akhilesh Raju Pusapati.The Registered office of the company is in Hyderabad. |
Unsupported Rating |
Not applicable |
Non-cooperation by the issuer/borrower |
Acuité has been requesting for No Default Statements (NDS); however, despite multiple requests; the Company’s management has remained non-cooperative and not submitted the NDS for the preceding 03 consecutive months. Acuité believes that information risk is a critical component in such ratings, and noncooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is therefore being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies. |
Limitation regarding information availability |
The rating is based on information available from sources other than the issuer/borrower (in the absence of information provided by the issuer/borrower). Acuité has endeavoured to gather information about the entity/industry from the public domain. Therefore, Acuité cautions lenders and investors regarding the use of such information, on which the indicative credit rating is based. |
Rating Sensitivities |
No information provided by the issuer / available for Acuite to comment upon. |
Liquidity Position |
No information provided by the issuer / available for Acuite to comment upon. |
Outlook: Not applicable |
|
Other Factors affecting Rating |
None |
Particulars | Unit | FY 23 (Actual) | FY 22 (Actual) |
Operating Income | Rs. Cr. | 0.00 | 0.00 |
PAT | Rs. Cr. | (0.29) | 0.00 |
PAT Margin | (%) | 0.00 | 0.00 |
Total Debt/Tangible Net Worth | Times | 0.00 | 0.00 |
PBDIT/Interest | Times | 0.00 | 0.00 |
Status of non-cooperation with previous CRA |
Not applicable |
Any other information |
None |
Applicable Criteria |
• Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm |
Note on Complexity Levels of the Rated Instrument |
In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite’s categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria “Complexity Level Of Financial Instruments” on www.acuite.in. |
|
|
|
|||||||||||||||||||||||||||
|
Contacts |
|
|
About Acuité Ratings & Research |
© Acuité Ratings & Research Limited. All Rights Reserved. | www.acuite.in |